Laia Crespo

Laia joined Sanofi Ventures in 2018 with a background in biotech. Prior to Sanofi, Laia was Investment Director for Ysios Capital, where she served on the Boards of OxThera, Minoryx Therapeutics, Inbiomotion and AM-Pharma. Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag (Johnson & Johnson). Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech.

Laia graduated in Chemistry from the University of Barcelona, where she also completed a PhD with honors. Laia holds an MBA from Cambridge Judge Business School, University of Cambridge.